Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-20Clinical Trial Update: To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 1, Phase 2]
A completed Phase 1/2 trial of belantamab mafodotin in combination with either lenalidomide-dexamethasone or bortezomib-dexamethasone for re…
-
CLINICAL_TRIALS trial_result · 2024-05-17Clinical Trial Update: Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]
A completed Phase 1 study evaluated wild-type reovirus in combination with carfilzomib and dexamethasone for relapsed or refractory multiple…
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study [Phase 1]
Phase 1 pilot study evaluating ixazomib with dexamethasone in patients with high-risk smoldering myeloma and multiple myeloma; the trial has…
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: Heart Rate Variability, Vagus Nerve and Cancer [NA]
The trial investigating heart rate variability and vagus nerve stimulation in cancer has been terminated. The listed conditions across the s…
-
CLINICAL_TRIALS trial_result · 2024-05-08Clinical Trial Update: STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS [Phase 2]
Phase 2 trial comparing three ixazomib-based regimens (ixazomib with dexamethasone; ixazomib with cyclophosphamide and dexamethasone; ixazom…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-05-08Clinical Trial Update: The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
This clinical trial update indicates the study on risk stratification in multiple myeloma using fluorescence flow cytometry to quantify circ…
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab [Phase 2]
Phase 2 trial evaluating daratumumab, azacitidine, and dexamethasone for recurrent or refractory multiple myeloma previously treated with da…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) [Phase 3]
Phase 3 trial comparing VELCADE-melphalan-prednisone vs Daratumumab with VMP in previously untreated multiple myeloma in the Asia-Pacific re…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma [Phase 1]
A Phase I safety, pharmacokinetic and pharmacodynamic study of KW-2478 in patients with multiple myeloma, chronic lymphocytic leukemia, or B…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma [Phase 1]
Phase 1 trial of an anti GM-2 monoclonal antibody for multiple myeloma has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-04-22Clinical Trial Update: A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
Pfizer's Elranatamab study in relapsed/refractory multiple myeloma has completed and posted results. The trial investigated the medicine in …
-
CLINICAL_TRIALS trial_result · 2024-04-19Clinical Trial Update: A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 1]
Phase 1 study of belantamab mafodotin in relapsed/refractory multiple myeloma has completed, with results posted detailing safety, tolerabil…
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 3]
Phase 3 trial comparing once-weekly versus twice-weekly carfilzomib in combination with lenalidomide and dexamethasone for relapsed or refra…
-
CLINICAL_TRIALS trial_result · 2024-04-12Clinical Trial Update: Stage I Multiple Myeloma Treatment [Phase 4]
A Phase 4 clinical trial update for stage I multiple myeloma has completed enrollment and treatment has been completed.
-
CLINICAL_TRIALS trial_result · 2024-04-09Clinical Trial Update: Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for ICP-490 in relapsed/refractory multiple myeloma across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2024-04-05Clinical Trial Update: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for CRD in carfilzomib-refractory multiple myeloma (Phase 1/2). Results have been posted as of 2024-04-05.
-
CLINICAL_TRIALS trial_result · 2024-04-03Clinical Trial Update: Bone Healing During Ninlaro Exposure [Phase 2]
Phase 2 clinical trial update examining bone healing during Ninlaro exposure in multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2024-04-03Clinical Trial Update: A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation [Phase 4]
A Phase 4 randomized, double-blind trial evaluating pentaisomaltose versus dimethyl sulfoxide for cryoprotection of autologous hematopoietic…
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
Results from Janssen's BCMA-targeted CAR-T therapy JNJ-68284528 in relapsed or refractory multiple myeloma were posted following a Phase 1/2…
-
CLINICAL_TRIALS trial_result · 2024-04-01Clinical Trial Update: Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients [Phase 1, Phase 2]
Phase 1/2 study of isatuximab as a single agent in Japanese relapsed and refractory multiple myeloma completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-29Clinical Trial Update: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy [Phase 2]
Phase 2 trial comparing KTd vs KRd induction therapy in newly diagnosed multiple myeloma and investigating a K-mono maintenance strategy; st…
-
CLINICAL_TRIALS trial_result · 2024-03-21Clinical Trial Update: Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation [Phase 2, Phase 3]
A multi-phase clinical trial assessing low-dose CTX as maintenance therapy for newly diagnosed multiple myeloma patients unsuitable for tran…
-
CLINICAL_TRIALS trial_result · 2024-03-18Clinical Trial Update: Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease [Phase 3]
Phase 3 trial comparing Narlumosbart with Denosumab in multiple myeloma bone disease is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM [Phase 1, Phase 2]
A combined belantamab mafodotin with aOX40 sub-study in relapsed/refractory multiple myeloma was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) [Phase 1, Phase 2]
Clinical trial update for CT053 in relapsed/refractory multiple myeloma (LUMMICAR STUDY 1) spanning Phase 1 and Phase 2.